Restaging locally advanced rectal cancer with mr imaging after chemoradiation therapy

Radiographics

Volumn 30, Issue 3, 2010, Pages 699-716

  Barbaro, Brunella ^a   Vitale, Renata ^a   Leccisotti, Lucia ^a   Vecchio, Fabio M ^a   Santoro, Luisa ^a   Valentini, Vincenzo ^a   Coco, Claudio ^a   Pacelli, Fabio ^a   Crucitti, Antonio ^a   Persiani, Roberto ^a   Bonomo, Lorenzo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTICLE; CANCER STAGING; HUMAN; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROGNOSIS; RECTUM TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 77953532658     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.303095085     Document Type: Article

References (74)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10-30.
2. Eddy DM. Screening for colorectal cancer. Ann Intern Med 1990;113(5):373-384.
3. Sagar PM, Pemberton JH. Surgical management of locally recurrent rectal cancer. Br J Surg 1996; 83(3):293-304.
4. Brown G. Thin section MRI in multidisciplinary pre-operative decision making for patients with rectal cancer. Br J Radiol 2005;78(spec no 2): S117-S127.
5. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection: histopathological study of lateral tumour spread and surgical excision. Lancet 1986;2(8514):996-999.
6. Valentini V, Coco C, Rizzo G, et al. Outcomes of clinical T4M0 extra-peritoneal rectal cancer treated with preoperative radiochemotherapy and surgery: a prospective evaluation of a single institutional experience. Surgery 2009;145(5):486-494.
7. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiation therapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345(9):638-646.
8. Improved survival with preoperative radiation therapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997;336(14):980-987.
9. Valentini V, Beets-Tan R, Borras JM, et al. Evidence and research in rectal cancer. Radiother Oncol 2008; 87(3):449-474.
10. Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 2003;90(3):355-364.
11. Beets-Tan RG, Beets GL, Vliegen RF, et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 2001;357(9255):497-504.
12. MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007;243(1):132-139.
13. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986;1(8496):1479-1482.
14. Sauer R, Becker H, Hohenberger W, et al. Preopera-tive versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351(17): 1731-1740.
15. Valentini V, Coco C, Minsky BD, et al. Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy. Int J Radiat Oncol Biol Phys 2008;70(2): 403-412.
16. Hiotis SP, Weber SM, Cohen AM, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 2002; 94(2):131-135; discussion 135-136.
17. Schell SR, Zlotecki RA, Mendenhall WM, Marsh RW, Vauthey JN, Copeland EM 3rd. Transanal excision of locally advanced rectal cancers downstaged using neoadjuvant chemoradiotherapy. J Am Coll Surg 2002;194(5):584-590; discussion 590-591.
18. Coco C, Manno A, Mattana C, et al. The role of local excision in rectal cancer after complete response to neoadjuvant treatment. Surg Oncol 2007;16 (suppl 1):S101-S104.
19. Buess G. Transanal microsurgery [in German]. Langenbecks Arch Chir Suppl Kongressbd 1991: 441-447.
20. Dresen RC, Beets GL, Rutten HJ, et al. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. I. Are we able to predict tumor confined to the rectal wall? Radiology 2009;252(1): 71-80.
21. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240(4): 711-717; discussion 717-718.
22. Zhang XM, Zhang HL, Yu D, et al. 3-T MRI of rectal carcinoma: preoperative diagnosis, staging, and planning of sphincter-sparing surgery. AJR Am J Roentgenol 2008;190(5):1271-1278.
23. Brown G, Daniels IR, Richardson C, Revell P, Peppercorn D, Bourne M. Techniques and troubleshooting in high spatial resolution thin slice MRI for rectal cancer. Br J Radiol 2005;78(927): 245-251.
24. Klessen C, Rogalla P, Taupitz M. Local staging of rectal cancer: the current role of MRI. Eur Radiol 2007;17(2):379-389.
25. Kim SH, Lee JM, Lee MW, Kim GH, Han JK, Choi BI. Sonography transmission gel as endo-rectal contrast agent for tumor visualization in rectal cancer. AJR Am J Roentgenol 2008;191(1): 186-189.
26. Barbaro B, Fiorucci C, Tebala C, et al. Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy. Radiology 2009;250(3): 730-739.
27. Suzuki C, Jacobsson H, Hatschek T, et al. Radio-logic measurements of tumor response to treatment: practical approaches and limitations. RadioGraphics 2008;28(2):329-344.
28. World Health Organization. WHO handbook for reporting results of cancer treatment. http://whqlibdoc.who.int/publications/9241700483.pdf. Accessed March 3, 2009.
29. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
30. Shia J, Guillem JG, Moore HG, et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol 2004;28(2):215-223.
31. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124(7):979-994.
32. Nagtegaal I, Gaspar C, Marijnen C, Van De Velde C, Fodde R, Van Krieken H. Morphological changes in tumour type after radiation therapy are accompanied by changes in gene expression profile but not in clinical behaviour. J Pathol 2004; 204(2):183-192.
33. Green JB, Timmcke AE, Mitchell WT, Hicks TC, Gathright JB Jr, Ray JE. Mucinous carcinoma: just another colon cancer? Dis Colon Rectum 1993;36 (1):49-54.
34. Umpleby HC, Ranson DL, Williamson RC. Peculiarities of mucinous colorectal carcinoma. Br J Surg 1985;72(9):715-718.
35. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoper-ative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer 1994;73(11): 2680-2686.
36. Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005;62(3):752-760.
37. Hussain SM, Outwater EK, Siegelman ES. Muci-nous versus nonmucinous rectal carcinomas: differentiation with MR imaging. Radiology 1999;213(1): 79-85.
38. Torkzad MR, Suzuki C, Tanaka S, Palmer G, Holm T, Blomqvist L. Morphological assessment of the interface between tumor and neighboring tissues, by magnetic resonance imaging, before and after radiation therapy in patients with locally advanced rectal cancer. Acta Radiol 2008;49(10): 1099-1103.
39. Vliegen RF, Beets GL, Lammering G, et al. Meso-rectal fascia invasion after neoadjuvant chemotherapy and radiation therapy for locally advanced rectal cancer: accuracy of MR imaging for prediction. Radiology 2008;246(2):454-462.
40. Koh DM, Chau I, Tait D, Wotherspoon A, Cunningham D, Brown G. Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2008;71(2):456-461.
41. Taylor FG, Swift RI, Blomqvist L, Brown G. A systematic approach to the interpretation of preopera-tive staging MRI for rectal cancer. AJR Am J Roentgenol 2008;191(6):1827-1835.
42. Rullier A, Laurent C, Vendrely V, Le Bail B, Bioulac-Sage P, Rullier E. Impact of colloid response on survival after preoperative radiation therapy in locally advanced rectal carcinoma. Am J Surg Pathol 2005; 29(5):602-606.
43. Allen SD, Padhani AR, Dzik-Jurasz AS, Glynne-Jones R. Rectal carcinoma: MRI with histologic correlation before and after chemoradiation therapy. AJR Am J Roentgenol 2007;188(2):442-451.
44. Chen CC, Lee RC, Lin JK, Wang LW, Yang SH. How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preop-erative combined chemoradiotherapy? Dis Colon Rectum 2005;48(4):722-728.
45. Kuo LJ, Chern MC, Tsou MH, et al. Interpretation of magnetic resonance imaging for locally advanced rectal carcinoma after preoperative chemoradiation therapy. Dis Colon Rectum 2005;48(1): 23-28.
46. Brown G, Richards CJ, Bourne MW, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 2003; 227(2):371-377.
47. Koh DM, Hughes M, Husband JE. Cross-sectional imaging of nodal metastases in the abdomen and pelvis. Abdom Imaging 2006;31(6):632-643.
48. Koh DM, Brown G, Temple L, et al. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings-initial observations. Radiology 2004;231(1):91-99.
49. Lahaye MJ, Engelen SM, Kessels AG, et al. USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. Radiology 2008;246(3):804-811.
50. Lahaye MJ, Beets GL, Engelen SME, et al. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. II. What are the criteria to predict involved lymph nodes? Radiology 2009;252(1): 81-91.
51. Valentini V, Coco C, Cellini N, et al. Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation. Int J Radiat Oncol Biol Phys 1999;45(5):1175-1184.
52. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007;188(6):1622-1635.
53. Ichikawa T, Erturk SM, Motosugi U, et al. High-B-value diffusion-weighted MRI in colorectal cancer. AJR Am J Roentgenol 2006;187(1):181-184.
54. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004;22(4):275-282.
55. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002;360 (9329):307-308.
56. Seierstad T, Roe K, Olsen DR. Noninvasive monitoring of radiation-induced treatment response using proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging in a colorectal tumor model. Radiother Oncol 2007; 85 (2):187-194.
57. Hein PA, Kremser C, Judmaier W, et al. Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol 2003;45(3):214-222.
58. Vandecaveye V, De Keyzer F, Nuyts S, et al. Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radia-tion therapy: correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys 2007;67(4):960-971.
59. de Bondt RB, Hoeberigs MC, Nelemans PJ, et al. Diagnostic accuracy and additional value of diffusion-weighted imaging for discrimination of malignant cervical lymph nodes in head and neck squamous cell carcinoma. Neuroradiology 2009;51 (3):183-192.
60. Ono K, Ochiai R, Yoshida T, et al. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases. J Magn Reson Imaging 2009;29(2):336-340.
61. Vriens D, de Geus-Oei LF, van der Graaf WTA, Oyen WJI. Tailoring therapy in colorectal cancer by PET-CT. Q J Nucl Med Mol Imaging 2009;53(2):224-244.
62. Glimelius B, Oliveira J; ESMO Guidelines Working Group. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(suppl 4):54-56.
63. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-1782.
64. Calvo FA, Domper M, Matute R, et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2004;58(2): 528-535.
65. Capirci C, Rampin L, Erba PA, et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radi-ation therapy. Eur J Nucl Med Mol Imaging 2007; 34(10):1583-1593.
66. Janssen MH, Ollers MC, Riedl RG, et al. Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using 18F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiat Oncol Biol Phys. 2009 Jul 29. [Epub ahead of print]
67. Cascini GL, Avallone A, Delrio P, et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 2006;47(8): 1241-1248.
68. Kubota R, Yamada S, Kubota K, Ishiwata K, Tama-hashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33(11): 1972-1980.
69. Capirci C, Rubello D, Chierichetti F, et al. Restag-ing after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET. Biomed Pharmacother 2004;58(8):451-457.
70. Heriot AG, Hicks RJ, Drummond EG, et al. Does positron emission tomography change management in primary rectal cancer? a prospective assessment. Dis Colon Rectum 2004;47(4):451-458.
71. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998;206(3):755-760.
72. Mardor Y, Pfeffer R, Spiegelmann R, et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 2003;21(6):1094-1100.
73. Theilmann RJ, Borders R, Trouard TP, et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 2004;6(6):831-837.
74. Harry VN, Semple SI, Gilbert FJ, Parkin DE. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 2008;111(2): 213-220.